-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
Souvenaid	B-I
on	O
plasma	O
micronutrient	O
levels	O
and	O
fatty	O
acid	O
profiles	O
in	O
mild	O
and	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
Subjects	B-P
with	I-P
mild	I-P
(	I-P
RCT1	I-P
,	I-P
RCT2	I-P
)	I-P
or	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
(	I-P
RCT3	I-P
)	I-P
received	O
active	O
or	O
control	O
product	O
once	O
daily	O
for	O
12	O
-	O
24	O
weeks	O
or	O
active	O
product	O
during	O
the	O
24	O
-	O
week	O
OLE	O
following	O
RCT2	O
(	O
n	O
=	O
212	O
-	O
527	O
)	O
.	O

Measurements	O
included	O
plasma	B-O
levels	I-O
of	I-O
B	I-O
vitamins	I-O
,	O
choline	B-O
,	O
vitamin	B-O
E	I-O
,	O
selenium	B-O
,	O
uridine	B-O
and	O
homocysteine	B-O
and	O
proportions	B-O
of	I-O
DHA	I-O
,	O
EPA	B-O
and	O
total	B-O
n	I-O
-	I-O
3	I-O
long	I-O
-	I-O
chain	I-O
polyunsaturated	I-O
fatty	I-O
acids	I-O
in	I-O
plasma	I-O
and	O
erythrocytes	B-O
.	O

Between	O
-	O
group	O
comparisons	O
were	O
made	O
using	O
t	O
tests	O
or	O
non	O
-	O
parametric	O
alternatives	O
.	O

-DOCSTART-	O

Title	O
:	O
Citalopram	B-I
for	O
the	O
Treatment	O
of	O
Agitation	O
in	O
Alzheimer	O
Dementia	O
:	O
Genetic	O
Influences	O
.	O

METHODS	O
:	O
We	O
utilized	O
data	O
from	O
the	B-I
Citalopram	I-I
for	O
Agitation	O
in	O
Alzheimer	O
'	O
s	O
Disease	O
(	O
CitAD	O
)	O
database	O
.	O

CitAD	O
was	O
a	O
9	O
-	O
week	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
clinical	O
trial	O
showing	O
significant	O
improvement	O
in	O
agitation	O
and	O
caregiver	O
distress	O
in	O
patients	O
treated	O
with	O
citalopram	B-I
.	O

Proportional	O
odds	O
logistic	O
regression	O
and	O
mixed	O
effects	O
models	O
were	O
used	O
to	O
examine	O
the	O
above	O
-	O
mentioned	O
outcome	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
the	B-I
Acetylcholine	I-I
Release	I-I
Agent	I-I
ST101	I-I
with	O
Donepezil	B-I
in	O
Alzheimer	O
'	O
s	O
Disease	O
:	O
A	O
Randomized	O
Phase	O
2	O
Study	O
.	O

METHODS	O
:	O
A	O
phase	O
2	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
enrolled	O
210	B-P
AD	I-P
patients	I-P
(	I-P
MMSE	I-P
10	I-P
-	I-P
20	I-P
)	I-P
on	O
10	B-I
mg	I-I
donepezil	I-I
QD	I-I
.	O

Patients	O
received	O
ST101	B-I
(	O
10	O
,	O
60	O
,	O
or	O
120	O
mg	O
QD	O
)	O
or	O
placebo	B-C
for	O
12	O
weeks	O
.	O

The	O
primary	O
endpoint	O
was	O
change	O
in	O
cognitive	B-O
function	I-O
measured	O
by	O
ADAS	B-O
-	I-O
cog	I-O
in	O
the	O
modified	O
Intent	O
To	O
Treat	O
(	O
MITT	O
)	O
population	O
and	O
the	O
Per	O
Protocol	O
(	O
PP	O
)	O
population	O
.	O

-DOCSTART-	O

Title	O
:	O
Nutritional	B-I
Guidance	I-I
Improves	O
Nutrient	O
Intake	O
and	O
Quality	O
of	O
Life	O
,	O
and	O
May	O
Prevent	O
Falls	O
in	O
Aged	B-P
Persons	I-P
with	I-P
Alzheimer	I-P
Disease	I-P
Living	I-P
with	I-P
a	I-P
Spouse	I-P
(	O
NuAD	O
Trial	O
)	O
.	O

METHODS	O
:	O
Randomised	O
controlled	O
trial	O
.	O

Persons	B-P
with	I-P
AD	I-P
living	I-P
with	I-P
a	I-P
spouse	I-P
.	O

Tailored	B-I
nutritional	I-I
guidance	I-I
with	O
home	O
visits	O
during	O
one	O
year	O
.	O

The	O
control	O
group	O
received	O
a	B-C
written	I-C
guide	I-C
about	O
nutrition	O
in	O
older	B-P
adults	I-P
and	I-P
all	I-P
community	I-P
-	I-P
provided	I-P
normal	I-P
care	I-P
.	O

The	O
primary	O
outcome	O
measure	O
was	O
weight	B-O
change	I-O
,	O
and	O
secondary	O
outcomes	O
included	O
changes	O
in	O
protein	B-O
and	O
micronutrient	B-O
intakes	I-O
from	I-O
three	I-O
-	I-O
day	I-O
food	I-O
records	I-O
,	O
HRQoL	B-O
(	I-O
15	I-O
D	I-O
)	I-O
and	O
rate	B-O
of	I-O
falls	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Changes	O
in	O
Brain	O
Volume	O
with	O
Bapineuzumab	B-I
in	O
Mild	O
to	O
Moderate	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
Bapineuzumab	B-I
dosages	O
included	O
0	O
.	O
5	O
mg	O
/	O
kg	O
in	O
carriers	O
and	O
0	O
.	O
5	O
or	O
1	O
.	O
0	O
mg	O
/	O
kg	O
in	O
noncarriers	O
,	O
every	O
13	O
weeks	O
for	O
78	O
weeks	O
.	O

Volumetric	O
outcomes	O
included	O
annualized	B-O
brain	I-O
,	O
ventricular	B-O
,	O
and	O
mean	B-O
hippocampal	I-O
boundary	I-O
shift	I-O
integrals	I-O
(	O
BBSI	B-O
;	O
VBSI	B-O
;	O
HBSI	B-O
)	O
up	O
to	O
Week	O
71	O
.	O

Treatment	O
differences	O
were	O
estimated	O
using	O
mixed	O
models	O
for	O
repeated	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Transcranial	B-I
direct	I-I
current	I-I
stimulation	I-I
as	O
a	O
memory	O
enhancer	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
in	O
which	O
tDCS	B-I
was	O
applied	O
in	O
six	O
30	O
-	O
minute	O
sessions	O
for	O
10	O
days	O
.	O

tDCS	B-I
was	O
delivered	O
to	O
the	O
left	O
temporal	O
cortex	O
with	O
2	O
-	O
mA	O
intensity	O
.	O

A	B-P
total	I-P
of	I-P
25	I-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
were	O
enrolled	O
in	O
the	O
study	O
.	O

All	O
of	O
the	O
patients	O
were	O
diagnosed	O
according	O
to	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke	O
and	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
criteria	O
.	O

Twelve	O
patients	O
received	O
active	B-I
stimulation	I-I
,	O
and	O
thirteen	O
patients	O
received	O
placebo	B-C
stimulation	I-C
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
change	O
in	O
two	B-O
parallel	I-O
versions	I-O
of	I-O
the	I-O
California	I-O
Verbal	I-O
Learning	I-O
Test	I-O
-	I-O
Second	I-O
Edition	I-O
,	O
a	B-O
standardized	I-O
neuropsychological	I-O
memory	I-O
test	I-O
normalized	I-O
by	I-O
age	I-O
and	I-O
gender	I-O
.	O

The	O
secondary	O
outcome	O
measures	O
were	O
the	B-O
Mini	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
clock	B-O
-	I-O
drawing	I-O
test	I-O
,	O
and	O
Trail	B-O
Making	I-O
Test	I-O
A	I-O
and	O
B	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
tolerability	O
of	O
BAN2401	B-I
-	O
-	O
a	O
clinical	O
study	O
in	O
Alzheimer	O
'	O
s	O
disease	O
with	O
a	B-I
protofibril	I-I
selective	I-I
A?	I-I
antibody	I-I
.	O

METHODS	O
:	O
Here	O
we	O
describe	O
the	O
first	O
clinical	O
study	O
with	O
BAN2401	B-I
.	O

Safety	B-O
and	O
tolerability	B-O
were	O
investigated	O
in	O
mild	O
to	O
moderate	O
AD	O
.	O

A	O
study	O
design	O
was	O
used	O
with	O
staggered	O
parallel	O
single	O
and	O
multiple	O
ascending	O
doses	O
,	O
from	O
0	O
.	O
1	O
mg	O
/	O
kg	O
as	O
a	O
single	O
dose	O
to	O
10	O
mg	O
/	O
kg	O
biweekly	O
for	O
four	O
months	O
.	O

The	B-O
presence	I-O
of	I-O
amyloid	I-O
related	I-O
imaging	I-O
abnormalities	I-O
(	O
ARIA	B-O
,	O
E	B-O
for	I-O
edema	I-O
,	O
H	B-O
for	I-O
hemorrhage	I-O
)	O
was	O
assessed	O
with	O
magnetic	B-O
resonance	I-O
imaging	I-O
(	I-O
MRI	I-O
)	I-O
.	O

Cerebrospinal	B-O
fluid	I-O
(	I-O
CSF	I-O
)	I-O
and	O
plasma	B-O
samples	I-O
were	O
analyzed	O
to	O
investigate	O
pharmacokinetics	B-O
(	I-O
PK	I-O
)	I-O
and	O
effects	B-O
on	I-O
biomarkers	I-O
.	O

-DOCSTART-	O

Title	O
:	O
R	B-I
-	I-I
and	O
S	B-I
-	I-I
citalopram	I-I
concentrations	O
have	O
differential	O
effects	O
on	O
neuropsychiatric	O
scores	O
in	O
elders	B-P
with	I-P
dementia	I-P
and	I-P
agitation	I-P
.	O

METHODS	O
:	O
Citalopram	B-I
enantiomer	O
exposures	O
(	O
AUC	O
(	O
0	O
,	O
24	O
h	O
)	O
)	O
derived	O
from	O
an	O
established	O
population	O
pharmacokinetic	O
analysis	O
were	O
utilized	O
to	O
explore	O
the	O
relationship	O
between	O
(	B-I
R	I-I
)	I-I
-	I-I
and	O
(	B-I
S	I-I
)	I-I
-	I-I
citalopram	I-I
area	O
under	O
the	O
curve	O
(	O
AUC	O
(	O
0	O
,	O
24	O
)	O
)	O
and	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Neurobehavioural	B-O
Rating	I-O
Scale	I-O
-	I-O
Agitation	I-O
Subscale	I-O
(	I-O
NBRS	I-O
-	I-O
A	I-O
)	I-O
,	O
modified	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
mADCS	I-O
-	I-O
CGIC	I-O
)	I-O
and	O
Neuropsychiatric	B-O
Inventory	I-O
Agitation	I-O
subscale	I-O
(	I-O
NPIA	I-O
)	I-O
scores	I-O
.	O

Time	O
dependent	O
changes	O
in	O
these	O
scores	O
(	O
disease	O
progression	O
)	O
were	O
accounted	O
for	O
prior	O
to	O
exploring	O
the	O
exposure	O
effect	O
relationship	O
for	O
each	O
enantiomer	O
.	O

These	O
relationships	O
were	O
evaluated	O
using	O
a	O
non	O
-	O
linear	O
-	O
mixed	O
effects	O
modelling	O
approach	O
as	O
implemented	O
in	O
nonmem	O
v7	O
.	O
3	O
.	O

-DOCSTART-	O

Title	O
:	O
Alzheimer	O
'	O
s	O
Disease	O
Severity	O
is	O
Not	O
Significantly	O
Associated	O
with	O
Short	B-I
Sleep	I-I
:	O
Survey	O
by	O
Actigraphy	O
on	O
208	B-P
Mild	I-P
and	I-P
Moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
Patients	I-P
.	O

METHODS	O
:	O
During	O
an	O
observational	O
first	O
step	O
of	O
a	O
clinical	O
trial	O
,	O
sleep	O
was	O
assessed	O
in	O
institutionalized	B-P
patients	I-P
with	I-P
mild	I-P
or	I-P
moderate	I-P
AD	I-P
using	O
actigraphy	B-O
(	O
MW8	B-O
,	O
Camtech	O
,	O
Cambridge	O
,	O
UK	O
)	O
for	O
14	O
consecutive	O
24	O
-	O
hour	O
periods	O
.	O

Sleep	O
parameters	O
analyzed	O
were	O
:	O
TST	B-O
,	O
time	B-O
in	I-O
bed	I-O
(	I-O
TIB	I-O
)	I-O
,	O
wake	B-O
after	I-O
sleep	I-O
onset	I-O
(	I-O
WASO	I-O
)	I-O
,	O
sleep	B-O
efficiency	I-O
(	I-O
SE	I-O
)	I-O
defined	O
by	O
the	B-O
ratio	I-O
TST	I-O
/	I-O
TIB	I-O
,	O
in	O
percentage	O
)	O
,	O
the	B-O
number	I-O
and	I-O
length	I-O
of	I-O
awakenings	I-O
,	O
the	B-O
night	I-O
fragmentation	I-O
index	I-O
,	O
the	B-O
interdaily	I-O
stability	I-O
,	O
and	O
intradaily	B-O
variability	I-O
indexes	I-O
.	O

Statistical	O
association	O
analyses	O
were	O
tested	O
between	O
these	O
values	O
and	O
AD	O
apathy	O
and	O
severity	O
scores	O
.	O

-DOCSTART-	O

Title	O
:	O
Cost	O
-	O
effectiveness	O
of	O
donepezil	B-I
and	O
memantine	B-I
in	O
moderate	O
to	O
severe	O
Alzheimer	O
'	O
s	O
disease	O
(	O
the	O
DOMINO	O
-	O
AD	O
trial	O
)	O
.	O

METHODS	O
:	O
Cost	O
-	O
effectiveness	O
analysis	O
was	O
based	O
on	O
a	O
52	O
-	O
week	O
,	O
multicentre	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
factorial	O
clinical	O
trial	O
.	O

A	B-P
total	I-P
of	I-P
295	I-P
community	I-P
-	I-P
dwelling	I-P
patients	I-P
with	I-P
moderate	I-P
/	I-P
severe	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
,	O
already	O
treated	O
with	O
donepezil	B-I
,	O
were	O
randomised	O
to	O
:	O
(	O
i	O
)	O
continue	O
donepezil	B-I
;	O
(	O
ii	O
)	O
discontinue	O
donepezil	B-I
;	O
(	O
iii	O
)	O
discontinue	O
donepezil	B-I
and	O
start	O
memantine	B-I
;	O
or	O
(	O
iv	O
)	O
continue	O
donepezil	B-I
and	O
start	O
memantine	B-I
.	O

-DOCSTART-	O

Title	O
:	O
Poor	O
Safety	O
and	O
Tolerability	O
Hamper	O
Reaching	O
a	O
Potentially	O
Therapeutic	O
Dose	O
in	O
the	O
Use	O
of	O
Thalidomide	B-I
for	O
Alzheimer	O
'	O
s	O
Disease	O
:	O
Results	O
from	O
a	O
Double	O
-	O
Blind	O
,	O
Placebo	O
-	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
24	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
study	O
with	O
escalating	O
dose	O
regimen	O
of	O
thalidomide	B-I
with	O
a	O
target	O
dose	O
of	O
400	O
mg	O
daily	O
in	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
.	O

The	O
primary	O
outcome	O
measures	O
were	O
tolerability	B-O
and	O
cognitive	B-O
performance	I-O
assessed	O
by	O
a	O
battery	O
of	O
tests	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
Term	O
Extensions	O
of	O
Randomized	O
Vaccination	O
Trials	O
of	O
ACC	B-I
-	I-I
001	I-I
and	O
QS	B-I
-	I-I
21	I-I
in	O
Mild	O
to	O
Moderate	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
Phase	O
2	O
a	O
extension	O
studies	O
of	O
randomized	O
parent	O
trials	O
were	O
conducted	O
in	O
the	O
United	O
States	O
,	O
European	O
Union	O
,	O
and	O
Japan	O
.	O

Four	O
immunizations	O
of	O
ACC	B-I
-	I-I
001	I-I
were	O
administered	O
at	O
the	O
same	O
3	O
dose	O
levels	O
(	O
3	O
,	O
10	O
,	O
and	O
30	O
?g	O
)	O
to	O
subjects	B-P
randomized	I-P
in	I-P
the	I-P
parent	I-P
studies	I-P
;	O
ACC	B-I
-	I-I
001	I-I
was	O
administered	O
with	O
QS	B-I
-	I-I
21	I-I
adjuvant	O
.	O

Safety	B-O
,	O
tolerability	B-O
,	O
and	O
immunogenicity	B-O
were	O
assessed	O
during	O
active	O
treatment	O
and	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Hearing	B-I
Aids	I-I
on	O
the	O
Cognitive	O
Status	O
of	O
Patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
and	I-P
Hearing	I-P
Loss	I-P
:	O
A	O
Multicenter	O
Controlled	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
A	O
multicenter	O
double	O
-	O
blind	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
was	O
conducted	O
in	O
patients	B-P
aged	I-P
more	I-P
than	I-P
65	I-P
years	I-P
.	O

A	O
group	O
was	O
equipped	O
with	O
active	B-I
HA	I-I
for	O
6	O
months	O
(	O
active	O
group	O
)	O
and	O
a	O
second	O
group	O
had	O
placebo	B-C
HA	I-C
for	O
6	O
months	O
(	O
placebo	O
group	O
)	O
followed	O
by	O
a	O
secondary	O
activation	O
phase	O
for	O
a	O
further	O
6	O
months	O
(	O
semi	O
crossover	O
procedure	O
)	O
.	O

Both	O
groups	O
were	O
retested	O
after	O
a	O
12	O
-	O
month	O
period	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
change	O
from	O
baseline	O
of	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
Cog	I-O
)	I-O
after	O
a	O
6	O
-	O
month	O
period	O
in	O
both	O
groups	O
and	O
after	O
6	O
months	O
of	O
secondary	O
HA	O
activation	O
in	O
the	O
placebo	O
group	O
.	O

A	O
smaller	O
cognitive	O
decline	O
should	O
be	O
obtained	O
with	O
HA	B-I
use	O
;	O
an	O
increase	O
in	O
ADAS	B-O
Cog	I-O
score	I-O
of	O
less	O
than	O
6	O
points	O
was	O
defined	O
a	O
success	O
.	O

-DOCSTART-	O

Title	O
:	O
Home	B-I
-	I-I
Based	I-I
Exercise	I-I
Program	I-I
Improves	O
Balance	O
and	O
Fear	O
of	O
Falling	O
in	O
Community	B-P
-	I-P
Dwelling	I-P
Older	I-P
Adults	I-P
with	I-P
Mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Pilot	O
Study	O
.	O

METHODS	O
:	O
A	O
prospective	O
randomized	O
controlled	O
parallel	O
-	O
group	O
trial	O
(	O
Wii	B-I
-	I-I
Fit	I-I
versus	O
walking	B-I
)	O
was	O
conducted	O
in	O
thirty	B-P
community	I-P
-	I-P
dwelling	I-P
older	I-P
adults	I-P
(	I-P
736	I-P
.	I-P
2	I-P
years	I-P
)	I-P
with	I-P
mild	I-P
AD	I-P
.	O

Home	B-I
-	I-I
based	I-I
exercises	I-I
were	O
performed	O
under	O
caregiver	O
supervision	O
for	O
8	O
weeks	O
.	O

Primary	O
(	O
Berg	B-O
Balance	I-O
Scale	I-O
,	I-O
BBS	I-O
)	O
and	O
secondary	O
outcomes	O
(	O
fear	B-O
of	I-O
falls	I-O
and	O
quality	B-O
of	I-O
life	I-O
)	O
were	O
measured	O
at	O
baseline	O
,	O
8	O
weeks	O
(	O
end	O
of	O
intervention	O
)	O
,	O
and	O
16	O
weeks	O
(	O
8	O
-	O
weeks	O
post	O
-	O
intervention	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
Safety	O
of	O
Citalopram	B-I
Compared	O
to	O
Atypical	B-C
Antipsychotics	I-C
on	O
Agitation	O
in	O
Nursing	B-P
Home	I-P
Residents	I-P
With	I-P
Alzheimer	I-P
Dementia	I-P
.	O

METHODS	O
:	O
Longitudinal	O
,	O
6	O
-	O
month	O
study	O
.	O

Nursing	O
home	O
(	O
NH	O
)	O
.	O

75	B-P
NH	I-P
residents	I-P
with	I-P
AD	I-P
and	I-P
agitation	I-P
,	O
randomized	O
to	O
citalopram	B-I
(	O
n	O
=	O
25	O
)	O
,	O
quetiapine	B-I
(	O
n	O
=	O
25	O
)	O
,	O
or	O
olanzapine	B-I
(	O
n	O
=	O
25	O
)	O
.	O

Changes	O
in	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
agitation	I-O
subscale	I-O
score	I-O
and	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
mADCS	I-O
-	I-O
CGIC	I-O
)	I-O
were	O
used	O
to	O
assess	O
treatment	O
efficacy	O
.	O

Participants	O
were	O
surveilled	O
for	O
adverse	B-O
health	I-O
outcomes	I-O
.	O

